Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.4
Journals
Medicina
Special Issues
Personalized Medicine for Patients with Respiratory Disease
share announcement

Personalized Medicine for Patients with Respiratory Disease

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Pulmonology".

Deadline for manuscript submissions: closed (12 March 2025) | Viewed by 1277

Special Issue Editor

Dr. Foteini Malli

E-Mail Website
Guest Editor
Faculty of Nursing, Respiratory Disorders Lab, University of Thessaly, Larissa, Greece
Interests: pulmonary embolism; chronic thromboembolic disease; venous thromboembolism; interstitial lung disease; respiratory nursing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The field of respiratory medicine has undergone remarkable advancements over the past few decades, significantly improving the diagnosis, treatment, and management of respiratory diseases. Traditionally, treatments for conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and pulmonary embolism have followed a one-size-fits-all approach. However, the heterogeneity observed in disease progression, response to treatment, and patient outcomes has necessitated a more nuanced approach. The concept of personalized medicine—tailoring medical treatment to the individual characteristics of each patient—has emerged as a transformative strategy in this context. With the advent of high-throughput technologies, advanced imaging, and bioinformatics, we are now equipped to analyze vast amounts of data at an unprecedented scale, paving the way for more precise and effective interventions in respiratory medicine.

This Special Issue on “Personalized Medicine for Patients with Respiratory Diseases” aims to explore the latest developments and innovations in this burgeoning field. Our objective is to provide a comprehensive overview of how personalized medicine is reshaping the landscape of respiratory healthcare. This includes advances in genomics, proteomics, metabolomics, and other omics technologies that are driving the development of personalized therapeutic strategies. We also aim to highlight the integration of clinical data with patient-reported outcomes and real-world evidence to enhance the precision of respiratory disease management. This Special Issue will feature cutting-edge research that showcases the application of personalized medicine to respiratory diseases. Topics of interest include, but are not limited to, the following:

- Genomic and molecular profiling of respiratory diseases.

- Development and validation of biomarkers for early diagnosis and prognosis.

- Personalized therapeutic approaches, including targeted therapies and biologics.

- The role of pharmacogenomics in tailoring drug treatments to individual patients.

- Integration of artificial intelligence and machine learning in personalized respiratory care.

- Case studies demonstrating the successful implementation of personalized treatment plans in clinical practice.

- Ethical, legal, and social implications of personalized medicine in respiratory care.

We invite submissions of original research articles, comprehensive reviews, systematic reviews, meta-analyses, case reports, and perspective pieces that contribute to the understanding and advancement of personalized medicine in respiratory diseases. We are particularly interested in papers that:

- Present novel findings from translational research that bridge the gap between bench and bedside.

- Offer insights into the development of new diagnostic tools and therapeutic interventions.

- Provide evidence from clinical trials or real-world studies on the efficacy and safety of personalized treatments.

- Explore innovative methodologies and technologies for data integration and analysis in personalized respiratory medicine.

- Discuss the policy, ethical, and implementation challenges associated with the adoption of personalized medicine in clinical practice.

This Special Issue aims to serve as a platform for researchers, clinicians, and healthcare professionals to share their latest findings and experiences, fostering collaboration and innovation in the pursuit of personalized healthcare solutions for patients with respiratory diseases. We look forward to receiving your contributions and advancing the field together.

Dr. Foteini Malli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized medicine respiratory diseases
  • targeted therapies
  • biomarkers
  • artificial intelligence
  • precision medicine
  • diagnostic tools

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 580 KiB  
Article
Analyzing Clinical Parameters and Bacterial Profiles to Uncover the COPD Exacerbations: A Focus on Intensive Care Unit Challenges
by Dragoș Huțanu, Hédi-Katalin Sárközi, Mara Andreea Vultur, Adrian-Horațiu Sabău, Iuliu Gabriel Cocuz, Corina Mărginean, Andra-Maria Chelemen and Corina Eugenia Budin
Medicina 2025, 61(4), 669; https://doi.org/10.3390/medicina61040669 - 5 Apr 2025
Viewed by 332
Abstract
Background and Objectives: Chronic obstructive pulmonary disease (COPD) poses a significant healthcare challenge worldwide, frequently leading to exacerbations necessitating intensive care unit admissions for potentially life-threatening complications. We aimed to investigate correlations between laboratory parameters, bacteriological agents, ventilation mode, and survival rates among [...] Read more.
Background and Objectives: Chronic obstructive pulmonary disease (COPD) poses a significant healthcare challenge worldwide, frequently leading to exacerbations necessitating intensive care unit admissions for potentially life-threatening complications. We aimed to investigate correlations between laboratory parameters, bacteriological agents, ventilation mode, and survival rates among COPD patients admitted to the ICU. Materials and Methods: Data were collected from the Pulmonology Department of Mures Clinical County Hospital, Romania, from 1 January 2022 to 30 October 2023. Eighty-four COPD patients required ICU transfer, except for concurrent SARS-CoV-2 infections. Results: Ventilation modes exhibited a significant correlation with specific bacteriological agents, orotracheal intubation being more prevalent in infections with Acinetobacter baumanii, Staphylococcus aureus, and Streptococcus pneumoniae (p < 0.001). Negative cultures were predominantly found in patients managed with non-invasive ventilation. Laboratory parameters revealed an association between elevated white blood cell counts and bacteriological superinfection, particularly with Escherichia coli (p < 0.001). Different bacteriological agents had different survival rates. Patients infected with Acinetobacter baumanii exhibited the highest mortality rate, while those with Staphylococcus aureus had the lowest (p < 0.01). Conclusions: The importance of prompt evaluation of laboratory parameters and bacteriological findings is underscored by these findings, particularly in ICU settings where ventilation and bacteriological profiles influence patient outcomes. The identification of elevated WBC counts is a marker of bacterial superinfection. The association between specific bacterial agents and ventilation modes highlights the importance of tailored treatment based on microbial profiles. These insights can be applied to refine treatment protocols and enhance survival rates in severe COPD exacerbations that require ICU management. Full article
(This article belongs to the Special Issue Personalized Medicine for Patients with Respiratory Disease)
►▼ Show Figures

Figure 1

14 pages, 311 KiB  
Article
Assessing Health-Related Quality of Life of Patients with Pulmonary Embolism with the Heart QoL Questionnaire
by Niki Gkena, Paraskevi Kirgou, Ioannis C. Lampropoulos, Evangelos C. Fradelos, Dimitrios Papagiannis, Zoe Daniil, Konstantinos I. Gourgoulianis and Foteini Malli
Medicina 2025, 61(3), 370; https://doi.org/10.3390/medicina61030370 - 20 Feb 2025
Viewed by 560
Abstract
Background and Objectives: While the acute phase of pulmonary embolism (PE) is well studied, its long-term physical and mental consequences have received less attention. Here, we aim to evaluate health-related quality of life (HRQoL) during the follow-up of PE with the Heart [...] Read more.
Background and Objectives: While the acute phase of pulmonary embolism (PE) is well studied, its long-term physical and mental consequences have received less attention. Here, we aim to evaluate health-related quality of life (HRQoL) during the follow-up of PE with the Heart QoL questionnaire and to assess its reliability and validity as a standardized tool. Materials and Methods: A prospective study was conducted at the PE Outpatient Clinic of the University Hospital of Larissa, enrolling 100 PE patients (63% male, mean age 56.97 ± 16.09 years). The internal consistency of the Heart QoL questionnaire was measured using Cronbach’s alpha. Correlations between Heart QoL and SF-36 subscales were examined. Results: We included 100 patients with PE (63% males, 56.97 ± 16.09 years). A total of 59% of the patients reported reduced functional capacity post-PE. Heart QoL demonstrated excellent reliability (Cronbach’s alpha = 0.947), with strong inter-item correlations (range: 0.337–0.949). Internal consistency coefficients for Heart QoL subscales were 0.558 (global), 0.606 (physical), and 0.871 (emotional). The inter-item correlation range from 0.337 to 0.949. Mean Heart QoL scores were significantly lower than the Greek norms (global: 2.15 ± 0.829, physical: 2.17 ± 0.86, emotional: 2.09 ± 1.03). Heart QoL subscales exhibit significant correlations, with most SF-36 subscales indicating strong convergent validity. In the multiple linear regression analysis, MRC, dyspnea, reduced functionality, and the presence of symptoms were independent predictors of Heart QoL global and physical score. The presence of bleeding complications and reduced functionality were independent predictors of Heart QoL emotional score. Conclusions: Heart QoL is a reliable and valid tool for assessing HRQoL in PE patients, offering an alternative to more time-consuming tools. Dyspnea, reduced functionality, and bleeding complications significantly impact long-term HRQoL, underscoring the need for structured, multidisciplinary follow-up care that integrates both physical and mental health support in order to optimize patient long-term outcomes, especially in those at risk for chronic thromboembolic consequences. Full article
(This article belongs to the Special Issue Personalized Medicine for Patients with Respiratory Disease)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop